Rubicon Research (RUBICON) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
14 Aug, 2026Executive summary
Q1 FY27 delivered strong financial performance with consolidated revenue from operations at INR 5,343 million, up 52% year-over-year, and EBITDA at INR 1,312 million, up 64.6%.
Net profit (PAT) reached INR 848 million, a 96% increase year-over-year, aided by a one-time insurance claim.
The quarter included the first consolidation of the Arinna acquisition, contributing INR 12 crore to revenue with negligible EBITDA impact.
Management transition announced: CFO Nitin Jajodia to become Chief Commercial Officer, with Rohit Saraogi as incoming CFO.
Two new product approvals received in Q1 FY27, maintaining a strong commercialization pace.
Financial highlights
Gross profit rose 46% year-over-year to INR 3,543 million, with gross margin up sequentially by 140 bps to 67.7%.
EBITDA margin improved to 24.6% from 22.4% a year ago.
EPS for the quarter was INR 5.08 (fully diluted), up 82.2% year-over-year.
Operating cash flow before working capital changes was INR 1,390 million; net operating cash flow was INR 285 million, impacted by delayed GST refunds.
Standalone and consolidated results were reviewed by independent auditors, with no material misstatements identified.
Outlook and guidance
Revenue visibility remains strong for upcoming quarters, with Q2 FY27 tracking for sequential USD revenue growth.
EBITDA margin guidance for FY27 revised upwards to at least 23%, despite anticipated ESOP, Arinna integration, and growth-related costs.
R&D spend guidance of INR 500 crore over nine quarters is on track, with current quarterly spend at INR 60 crore.
Latest events from Rubicon Research
- Quarterly net profit of ₹255.65 million on revenue of ₹3,167.19 million, driven by US sales.RUBICON
Q1 25/26 - FY26 saw robust revenue and profit growth, a successful IPO, and a recommended ₹1.50 dividend.RUBICON
Q4 25/26 - Revenue up 50% YoY, net profit at ₹13,436 lakhs, and major US acquisition completed.RUBICON
Q4 24/25 - Strong revenue and profit growth, successful IPO, and strategic biotech investments.RUBICON
Q2 25/26 - Strong revenue and profit growth, successful IPO, and strategic investments marked the quarter.RUBICON
Q3 25/26